fbpx Yourgene Health plc - Home
001-news.jpg
002-news.jpg
004-news.jpg
003-news.jpg
DSC00185r.jpg
previous arrow
next arrow

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Elucigene DPYD tests to be used routinely in Wales

Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely screen all cancer patients prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.

Wales is the first nation in the UK to implement this screening programme and offer the DPYD test to all patients, with over 400 samples already taken and 6% of patients coming back positive. All Wales Medical Genomics Service (AWMGS), which provides specialist genetic services to individuals with, or concerned about rare genetic conditions, commenced a pilot phase earlier this year which was successful, leading to the launch of the service this week. It has led to all health boards across Wales routinely offering the DPYD test to cancer patients, of which Yourgene is the sole provider.

Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.

Yourgene will be providing the Elucigene DPYD tests to screen for approximately 200 patients each month for the next year. If 2,400 patients are screened, at the positive rate of 6% continues, we anticipate 144 cancer patients will be prevented from having toxic chemotherapy reactions.

Lyn Rees, CEO of Yourgene, commented: “It is fantastic to see this form of personalised medicine implemented across Wales, allowing the quality of care for cancer patients to improve, ultimately saving lives. Yourgene is proud to be sole supplier of DPYD so soon after its launch in September 2019 and looks forward to similar schemes being rolled out across the UK.”

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



  • 25 January 2023 - Directorate Change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate Change

    Manchester, UK - 25 January 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that further to the announcement made on the 21 December 2022 regarding the evolution of the Board, Andrew (“Andy”) Leeser has been appointed as a Non-executive Director (“NED”) with immediate effect.

    Andy is one of the UK’s most experienced mid-market corporate transformation specialists. He has been involved with

    Read More
  • 3 November 2022 - First half trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    First half trading update

    Manchester, UK – 03 November 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the six months ended 30 September 2022 (“H1 FY23”).

    Highlights
    Core revenues for H1 FY23, i.e. excluding COVID-related activities, were £8.0m (H1 FY22: £7.0m), an increase of 14%. Total revenues on a statutory basis were £9.6m (H1 FY22: £17.5m) reflecting

    Read More
  • 29 September 2022 - Yourgene Health Receives HSA approval for IONA Nx NIPT Workflow in Singapore +

    Yourgene Health plc
    ("Yourgene" or the "Company")
     
    Yourgene Health Receives HSA approval for IONA Nx NIPT Workflow in Singapore
    • IVD prenatal screening workflow to help improve access to non-invasive genetic screening for patients and clinicians
    • Company continues to expand global access to products as it scales up revenue opportunities

    Manchester, UK, 29 September 2022: Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, today announced it has received Health Sciences Authority

    Read More
  • 27 September 2022 - AGM Statement +

    Yourgene Health plc
    ("Yourgene" or the "Company")
     
    AGM statement
     
    Manchester, UK – 27 September 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (“AGM”) at 2:00pm today.
     
    At the meeting, Dr John Brown CBE, Non-executive Chairman, will make the following statement:
     
    ‘It is a pleasure to be at my first AGM as Chairman of Yourgene after 3 years on the Board as a Non-executive Director.
    Read More
  • 25 Aug 2022 - Notice of AGM, Change of Registered Address and Investor Presentation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Notice of AGM, Change of Registered Address and
    Investor Presentation

    Manchester, UK – 25 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy will shortly be available on the Company's website at:  www.yourgene-health.com/investors/key-documents/shareholder-communications  and are being posted to those shareholders who have opted out of electronic communications.

    The majority of Yourgene shareholders

    Read More
  • 16 August 2022 - Open Day and advance notice of AGM +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Open Day and advance notice of AGM

    Manchester, UK – 16 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be hosting an Open Day at its new facilities on Manchester Science Park, Manchester, UK on Tuesday 27 September 2022 from 3pm to 6pm, welcoming shareholders, analysts and other interested stakeholders.

    The Open Day will follow immediately after the Company’s Annual General Meeting (“AGM”)

    Read More
  • 27 July 2022 - Dr John Brown CBE confirmed as Chairman +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Dr John Brown CBE confirmed as Chairman

    Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, confirms the appointment of Dr John Brown CBE as Chairman to the Group with immediate effect.

    Dr Brown’s appointment as Chairman was announced on 26 April 2022 and was expected to take effect at the Company’s upcoming AGM in September 2022. He has been

    Read More
  • 27 July 2022 - Audited Final Results +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Audited Final Results 
     
    Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its final results for the financial year ended 31 March 2022 (“FY22”), and provides an unaudited update on trading for the first quarter of the current financial year (“Q1 FY23”). 
     
    The Group’s performance in FY22 reflects the significant revenue growth delivered from COVID-related products and services,
    Read More
  • 24 May 2022 - Launch of the Accelerator Phase for Microdeletions Plugin +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of the Accelerator Phase for Microdeletions Plugin
    Expanding the clinical menu and capabilities of IONA® Nx NIPT Workflow offering

    Manchester, UK –  24 May 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of Yourgene’s Accelerator Phase for its Microdeletions 1 Plugin (the “Plugin”), which expands on the clinical menu and capabilities of the class leading IONA ® Nx NIPT Workflow

    Read More
  • 26 April 2022 - Directorate Change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate Change

    Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from his position as Chairman, at the Company’s next Annual General Meeting (“AGM”). The Board is pleased to confirm that he will remain on the Board as a Non-executive Director.

    Dr John Brown CBE, currently a Non-executive Director

    Read More
  • 26 April 2022 - Full year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year trading update

    Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the year ended 31 March 2022 (“FY22”).

    FY22 performance in line with upgraded guidance

    Revenues for FY22 were £37.6m, up 105% on the previous year and in line with recently upgraded guidance.

    Genomic Services (“GS”) revenues up 239% to £21.6m

    Read More
  • 25 April 2022 - Strategic partnership extended with Ambry Genetics +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Strategic partnership extended with Ambry Genetics
    Expanding market access of technology

    Manchester, UK – 25 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has extended its strategic partnership with Ambry Genetics (‘Ambry’), a leading US precision medicine company, with a new Genomic Services collaboration. The new agreement will allow both companies access to each other’s technology and assays, expanding market access and penetration

    Read More
  • 06 April 2022 - Capital Markets Day +

    Yourgene Health plc

    (“Yourgene”  or the “Company”)

    Capital Markets Day

    Manchester, UK – 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April 2022.
     
    The event will provide investors with a compelling opportunity to hear more from other senior members of the management team about the roadmap and growth plans for certain products and services, both in North
    Read More
  • 17 February 2022 - Successful CTDA desktop review +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Successful CTDA desktop review
    Approval for sale of Clarigene® SARS-CoV-2 Test in the UK

    Manchester, UK - 17 February 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that it has received confirmation from the UK Health Security Agency that the Clarigene® SARS-CoV-2 test (CE-IVD) (“Clarigene ® ”) has been approved under the requirements set out in the Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations

    Read More
  • 25 January 2022 - Directorate Change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate Change

    Manchester , UK - 25 January 2022 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director (“NED”) and Chair of the Audit Committee at Yourgene with effect from today.

    Mary has extensive experience in the healthcare sector, having previously been Chief Financial Officer and board member of AIM listed Advanced Medical Solutions plc (“AMS”) for

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen